Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.
Soluble Galectin-1 (sGal-1, also termed LGALS1), soluble CD163 (sCD163) and soluble CD30 (sCD30) have been reported to be elevated in plasma or serum of patients with classical Hodgkin lymphoma (cHL). We aimed to determine the clinical utility of these biomarkers for evaluation of treatment response compared to thymus and activation regulated chemokine (TARC, also termed CCL17). Plasma or serum samples were prospectively collected among 103 newly diagnosed cHL patients before and after treatment. Levels of sGal-1, sCD163, sCD30 and TARC were correlated with disease characteristics and clinical treatment response. Elevated plasma levels of sGal-1, sCD163, sCD30 and TARC were found in 67%, 21%, 91% and 93% of cHL patients respectively. Mean plasma levels of sGal-1 and sCD30 decreased after treatment but sCD163 did not decrease after treatment. There was no correlation with change of these markers and clinical treatment response in individual patients. TARC levels strongly correlated with disease characteristics and metabolic volume. TARC remained high in 6 out of 7 non-responsive patients and dramatically decreased in 95 out of 96 responsive patients. In summary, elevated pre-treatment levels of sGal-1, sCD163, sCD30 and TARC can be found in patients with cHL. However, only plasma TARC accurately reflects disease activity and correlates with clinical treatment response.
Department of Haematology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Wouter J
WJ
Plattel
Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Zainab N D
ZN
Alsada
Department of Haematology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Gustaaf W
GW
van Imhoff
Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Arjan
A
Diepstra
Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Anke
A
van den Berg
Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Lydia
L
Visser
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000097:blood; D015214:Antigens, Differentiation, Myelomonocytic / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D054414:Chemokine CCL17 / Q000097:blood; D005260:Female; D037483:Galectin 1 / Q000097:blood; D006689:Hodgkin Disease / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011956:Receptors, Cell Surface / Q000097:blood; D016896:Treatment Outcome; D055815:Young Adult; D000098902:CD163 Antigen
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; C106230:CCL17 protein, human; D000098902:CD163 Antigen; D054414:Chemokine CCL17; D037483:Galectin 1; D017730:Ki-1 Antigen; C445499:LGALS1 protein, human; D011956:Receptors, Cell Surface
Hodgkin lymphoma; biomarker; circulating; thymus and activation regulated chemokine; treatment response